奥兰扎平治疗精神分裂症58例临床观察  

Clinical investigation of treating schizophrenia with olanzapine

作　　者：张新波[1] 谢世平[1] 范俭雄[1] 姚辉[1] 李海林[1] 张宁[1] 张心保[1] 

机构地区：[1]南京医科大学附属脑科医院,江苏南京210029

出　　处：《东南大学学报（医学版）》2002年第4期324-325,共2页Journal of Southeast University(Medical Science Edition)

摘　　要：目的 :观察奥兰扎平治疗精神分裂症的临床疗效与安全性。方法 :选择 5 8例精神分裂症病人 ,开始给予奥兰扎平 5mg·d-1,3d后根据临床疗效、副反应情况酌情增加剂量 ,最大剂量不超过 2 0mg·d-1,治疗 8周。治疗前及治疗后每 2周用PANSS、CGI、TESS量表评定 1次。结果 :治疗后PANSS总分、各因子分较治疗前显著下降 (P <0 .0 1) ,副反应主要有抗胆碱症状、过度镇静、体重增加、一过性丙氨酸氨基转移酶升高。结论 :奥兰扎平是一种安全、有效。Objective To explore the effect and safety of olanzapine.Methods 58 in-patients diagnosed as schizophrenia according to CCMD2R had been given olanzapine at least for 8 weeks.The dosage was 5mg·d -1 at the beginning.Afterwards,the dosage was adjusted according to clinical effect and side effect,and the maximum dosage was no more than 20mg·d -1.PANSS,CGI and TESS were evaluated before treatment and every other 2 weeks after treatment.Result PANSS total score and all factors score were significantly lower (P<0.01) in the end of treatment than in the beginning.The side effects were mainly antimuscarinic activity,somnolence,weight gain,transitory and reversible ALT increasing.Conclusion Olanzapine is one of the effective and safe antipsychotics.

关 键 词：奥兰扎平 精神分裂症 药物治疗 副作用 

分 类 号：R749.3[医药卫生—神经病学与精神病学]